Phase Ib study of durvalumab (MEDI 4736) in combination with anti-CD19 CAR transduced T cells in patients with patients with non-Hodgkin's lymphoma

Trial Profile

Phase Ib study of durvalumab (MEDI 4736) in combination with anti-CD19 CAR transduced T cells in patients with patients with non-Hodgkin's lymphoma

Planning
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2015

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary) ; Durvalumab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Juno Therapeutics; MedImmune
  • Most Recent Events

    • 28 Apr 2015 New trial record
    • 23 Apr 2015 MedImmune and Juno Therapeutics have announced an immuno-oncology clinical trial collaboration and will jointly co-fund this initial phase Ib study, which is expected to begin in 2015, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top